Stevanato Group (NYSE:STVN) announced today that it expanded its corporate headquarters with a new facility in Italy.
Based in Piombino Dese, Italy, Stevanato Group said the 6,750-square-meter facility will support the optimization of its industrial footprint while advancing operations and growth within the company.
About 2,500 square meters of the facility will be dedicated to increasing production of high-value products, with new glass syringe forming lines devoted to producing EZ-Fill solutions (pre-sterilized drug containment solutions) added to hosting offices, an Italian analytical services site and R&D space, the company said in a news release.
Construction of the new building began in September 2021. Stevanato Group plans to install and validate new lines in the second quarter of 2022 with expectations for beginning industrial production late in the second quarter or early in the third quarter.
The new facility falls in line with Stevanato Group’s 2020-2023 industrial plan, as the company recently operationalized two additional lines for EZ-Fill vials and syringes manufacturing in Italy with plans to add two more lines devoted to EZ-Fill syringes and one for Alba syringes.
The company announced plans last month to construct a facility in Fishers, Indiana, to be closer to its North America-based pharmaceutical customers and provide an additional supply source for its mission-critical products.
“We are very proud of the global growth and evolution that Stevanato Group has achieved over the recent years, and we are always exploring new opportunities and ways to meet our customers’ needs,” Stevanato Group CEO Franco Moro said in the news release. “Further increasing our production capabilities here at home through this new space we expect to be able to bridge capacity demands while our exciting projects in the U.S. and China are underway.”